Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (161-170 of 190) with videos related to

Pageof 19
Sort By:
Arthritis and Rheumatism|December 1, 2007
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysisEdward Keystone, Roy Fleischmann, Paul Emery, et al.
RMD Open|March 21, 2018
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritisDésirée van der Heijde, Atul Deodhar, Oliver FitzGerald, et al.
Arthritis Research & Therapy|April 22, 2023
The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb studyPaul Emery, Yoshiya Tanaka, Vivian P Bykerk, et al.
The New England Journal of Medicine|January 26, 2022
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid ArthritisSteven R Ytterberg, Deepak L Bhatt, Ted R Mikuls, et al.
Rheumatology (Oxford, England)|August 28, 2012
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb studyMichael E Weinblatt, Roy Fleischmann, Tom W J Huizinga, et al.
RMD Open|December 30, 2022
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritisChun Wu, Yanhua Hu, Peter Schafer, et al.
The Journal of Rheumatology|January 15, 2025
Association Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 StudyPaul Emery, Roy Fleischmann, Robert Wong, et al.
Annals of the Rheumatic Diseases|February 11, 2025
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
RMD Open|November 14, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature researchAndreas Kerschbaumer, Josef S Smolen, Peter Nash, et al.
The New England Journal of Medicine|August 10, 2012
Tofacitinib or adalimumab versus placebo in rheumatoid arthritisRonald F van Vollenhoven, Roy Fleischmann, Stanley Cohen, et al.
Pageof 19

Showing results (161-170 of 190) with videos related to

Sort By:
Pageof 19
Arthritis and Rheumatism|December 1, 2007
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysisEdward Keystone, Roy Fleischmann, Paul Emery, et al.
RMD Open|March 21, 2018
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritisDésirée van der Heijde, Atul Deodhar, Oliver FitzGerald, et al.
Arthritis Research & Therapy|April 22, 2023
The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb studyPaul Emery, Yoshiya Tanaka, Vivian P Bykerk, et al.
The New England Journal of Medicine|January 26, 2022
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid ArthritisSteven R Ytterberg, Deepak L Bhatt, Ted R Mikuls, et al.
Rheumatology (Oxford, England)|August 28, 2012
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb studyMichael E Weinblatt, Roy Fleischmann, Tom W J Huizinga, et al.
RMD Open|December 30, 2022
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritisChun Wu, Yanhua Hu, Peter Schafer, et al.
The Journal of Rheumatology|January 15, 2025
Association Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 StudyPaul Emery, Roy Fleischmann, Robert Wong, et al.
Annals of the Rheumatic Diseases|February 11, 2025
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
RMD Open|November 14, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature researchAndreas Kerschbaumer, Josef S Smolen, Peter Nash, et al.
The New England Journal of Medicine|August 10, 2012
Tofacitinib or adalimumab versus placebo in rheumatoid arthritisRonald F van Vollenhoven, Roy Fleischmann, Stanley Cohen, et al.
Pageof 19